Ruth Atkins was given the jab in her arm and then carefully monitored by doctors for any side effects.
She is the first of 60 healthy volunteers to
take part in a clinical trial at Oxford University's Jenner Institute.
She was paid just £380 - not for the risk, but
for any loss of earnings.
An hour after having the vaccine she said:
"I feel absolutely fine. It felt no different to being vaccinated before
going on holiday.
"I volunteered because the situation in
West Africa is so tragic and I thought being part of this vaccination process
was something small I could do to hopefully make a huge impact."
The tests are taking place
at the University of Oxford
The vaccine is made from a harmless chimpanzee
virus that has been genetically modified to carry a benign payload of ebola
DNA.
The genetic material will make a single ebola
protein in the body - not enough to cause the disease, but enough to prime the
immune system to attack the virus in future.
The volunteers will be given different doses
and then monitored for side effects and their immune response.
Workers burn ebola
protection clothing in Guinea
Trials in monkeys have shown the vaccine is
100% effective in the first month, with some protection remaining 10 months
later.
Professor Adrian Hill, who is leading the
research team, said: "These are initial safety trials of the vaccine and
it will be some time before we know whether the vaccine could protect people
against ebola.
"But we are optimistic that the candidate
vaccine may prove useful against the disease in the future."
Scientists and medicines regulators are
fast-tracking the testing process, which would normally take at least 18
months.
Liberia is one of the
country's struggling with the epidemic
They hope to start widespread use of the
vaccine in West Africa early next year.
The manufacturer, GlaxoSmithKline, will scale
up production even while testing is under way, so 10,000 doses will be ready to
be sent out to Liberia, Sierra Leone and Guinea as soon as the vaccine is given
the green light.
The vaccine has been welcomed by Professor
Peter Piot, who discovered the ebola virus, and is now director of the London
School of Hygiene and Tropical Medicine.
He told Sky News the vaccine should be given
to healthcare workers who are at high risk of becoming infected.
But he warned there would not be enough doses
to protect whole communities and "tens and tens of thousands" would
still die.
"Whether this new vaccine will be useful
to stop the epidemic I don't know," he said.
President Obama has warned
the epidemic is spiralling out of control.
"Let's hope the epidemic will be nearly
finished by the end of the year, or in six months' time.
"If it lasts much longer the vaccine will
be there. But let's not forget there will be other epidemics."
Almost 5000 people have so far been infected
by the virus in West Africa - half of them have died.
But worryingly the epidemic is accelerating,
with half the cases occurring in just the last three weeks.
Professor Hill said: "Witnessing the
events in Africa makes it clear that developing new drugs and vaccines against
ebola should now be an urgent priority.
"It is tremendous that so many people
have worked hard to make this trial happen in short time, and I am enormously
grateful to those volunteers who have come forward to take part."
The trial has been funded by a £2.8m grant
from the Wellcome Trust, the Medical Research Council and the UK Department for
International Development.
Foreign Secretary Philip Hammond has announced
further UK support to tackle ebola in West Africa, including providing 700
treatment beds in Sierra Leone.
Sky News
she get liver
ReplyDeleteVery brave, don't want any chimapanze substance in my body
ReplyDeleteso nice of her
ReplyDelete